Invasive candidiasis in the ICU: evidence based and on the edge of evidence.
Invasive candidiasis is a common nosocomial infection among critically ill patients, constitutes an important cause of sepsis, and is associated with significant morbidity and mortality. The Infectious Diseases Society of America (IDSA) has created evidence-based guidelines for the management of invasive candidiasis. However, several new antifungal agents with excellent activity against Candida spp. and favourable safety profiles have been introduced successfully in the clinical setting since the IDSA guidelines were published in late 2003. Further, the role of antifungals is not entirely clear in the intensive care unit (ICU) setting. Therefore, this article discusses daily problems in the prophylaxis and treatment of invasive candidasis in interdisciplinary ICUs.
Hollenbach
Eike
E
Interdisciplinary Intensive Care Unit, Department of Medicine, University of Leipzig, Leipzig, Germany. eike.hollenbach@medizin.uni-leipzig.de
D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D002175:Candida; D002177:Candidiasis / Q000188:drug therapy / Q000517:prevention & control*; D003428:Cross Infection / Q000188:drug therapy / Q000517:prevention & control; D003840:Deoxycholic Acid / Q000627:therapeutic use; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D054714:Echinocandins / Q000627:therapeutic use; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D007362:Intensive Care Units; D017964:Itraconazole / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012307:Risk Factors; D014230:Triazoles / Q000627:therapeutic use; D065819:Voriconazole
D000935:Antifungal Agents; D004338:Drug Combinations; D054714:Echinocandins; D011743:Pyrimidines; D014230:Triazoles; D003840:Deoxycholic Acid; D017964:Itraconazole; C101425:posaconazole; D000666:Amphotericin B; C059765:amphotericin B, deoxycholate drug combination; D015725:Fluconazole; D065819:Voriconazole